DURVALUMAB | B761069 | ASTRAZENECA UK LTD
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | May. 1, 2029 | Active | Computed |
| 7-Year Orphan | Dec. 4, 1931 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12435133(composition) · relevance 82/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 51 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Bristol-Myers Squibb Co. et al v. AstraZeneca Pharmaceuticals LP et al 1 patentdurvalumab (IMFINZI); nivolumab (OPDIVO) | D. Del. | 2023-04-25 | Terminated 2023-07-31 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.